Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study
Launched by RECKITT BENCKISER LLC · Oct 26, 2010
Trial Information
Current as of July 09, 2025
Completed
Keywords
ClinConnect Summary
RB has developed a fixed-dose combination of ibuprofen and acetaminophen (paracetamol). Since the pharmacological actions of ibuprofen and acetaminophen (paracetamol) differ in their site and mode of action, the combination would be expected to be more effective than either active alone, given that pain is multi-factorial with different mediators.
The purpose of this study was to compare the efficacy and tolerability of ibuprofen/acetaminophen (paracetamol) combination with leading market analgesics.
The efficacy and tolerability was assessed in terms of total analgesic effect, peak analg...
Gender
ALL
Eligibility criteria
- Main Inclusion Criteria:
- • Experiencing moderate to severe pain after extraction of impacted third molars
- Main Exclusion Criteria:
- • Any ongoing painful condition other than that associated with the current third molar surgery that could significantly interfere with the subject's suitability Any condition that would render the subject unsuitable to receive an NSAID, acetaminophen or codeine
About Reckitt Benckiser Llc
Reckitt Benckiser LLC is a global consumer health and hygiene company dedicated to innovating and delivering products that enhance the well-being of individuals and families. With a strong commitment to science and research, Reckitt Benckiser conducts clinical trials to evaluate the efficacy and safety of its health-related products. Leveraging decades of expertise in consumer health, the company aims to provide high-quality solutions that address everyday health needs, contributing to healthier lives and communities worldwide. Through rigorous clinical research, Reckitt Benckiser continuously seeks to advance its product offerings and uphold its standards of excellence in the health and hygiene sectors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Austin, Texas, United States
Patients applied
Trial Officials
Stephen Daniels
Principal Investigator
Premier Research Group Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials